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ABSTRACT 
The Effects of Bicuculline on Cocaine Self-Administration in Male Rats 
Developmentally Exposed to Lead. (August 2003) 
Rodrigo Valles Jr., B.A., University of Texas at Austin 
 
Chair of Advisory Committee: Dr. Jack R. Nation 
 
 
 
Rationale: Lead-exposure during developmental periods may alter reinforcing patterns of 
drugs of abuse in adulthood.  Anxiety related mechanisms may also influence drug 
intake. Interactions between the two altering factors may exist.  Objectives: The present 
study examined the effects of perinatal lead-exposure on cocaine self-administration after 
a GABAA antagonist pre-treatment.  Methods: Female rats were exposed to a regimen of 
16 mg lead daily for 30 days prior to breeding with un-exposed males.  This continued 
throughout gestation and lactation until postnatal day (PND) 21.  On PND 63, animals 
were implanted with indwelling jugular catheters. After a 7 day recovery period, animals 
were trained to self-administer 0.50 mg/kg cocaine intravenously [IV].  After stable 
responding had been established, testing procedures began using combinations of 0.03 
and 0.06 mg/kg cocaine [IV] and 0.00, 0.50, 1.00 and 2.00 mg/kg bicuculline (a GABAA 
antagonist) intraperitoneal [IP].  Results: Bicuculline pre-treatment caused directionally 
opposite effects in both treatment groups (Group 0-Lead and Group 16-Lead) at the 0.06 
mg/kg cocaine dose.  Group 0-Lead animals showed an increase in self-administration, 
while Group 16-Lead animals showed a decrease in responding on the active (cocaine) 
lever. Results at the 0.03 mg/kg cocaine dose showed no discernable pattern.  Group 0-
Lead animals decreased in active lever responding at the 2.00 mg/kg bicuculline dose.  
iv 
Group 16-Lead animals showed no differences in responding at any dose of bicuculline. 
Conclusions:  These data further suggest the influential role of GABA in mediating 
cocaine reward and the ability of developmental lead-exposure to alter mechanisms 
mediating drug responsiveness even after exposure has terminated.   
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INTRODUCTION 
Lead (Pb) contamination continues to be one of the major pollution problems in North 
America despite increased governmental regulations targeted to reduction of selected 
contaminants. Various routes of exposure to humans exist, of which most seem to be 
concentrated in inner cities (Harwell et al., 1996; Pirkle et al., 1998).  Many of these 
urban communities have substandard living areas where residents do not possess the 
resources to protect themselves against toxicity-related health hazards.  Lack of proper 
monitoring of lead safety levels in these areas has resulted in proliferation of exposure 
vectors.  Substandard areas are often near industrial sections of a city or heavy traffic 
areas.  Lead particles in the air, dust, soil, or water supply of these communities can often 
be a source for lead ingestion or inhalation.  Occupational exposure can be directly 
dangerous for smelters, plumbers, welders, or paint plant workers and indirectly to their 
families since particles are often brought home on their clothes and shoes.  Lead based 
paints and dust inhalation are a common source of non-occupational hazard.   
Of particular concern are issues related to prenatal/postnatal exposure in children, 
who are especially at risk of being exposed to the effects of lead directly and/or via the 
mother during critical developmental periods.   Inner city reports of lead-exposure state 
that up to 70% of children may be exposed to lead at clinically unsafe levels (Mielke, 
1999). Continuous exposure, even at low levels, via inhalation or ingestion in children 
may result in cognitive and physiological deficiencies and subsequent behavioral 
alterations that could last well into adulthood (Godwin, 2001).  Moreover, lead  
_____________________________ 
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distribution to the fetus or newborn may have serious consequences because of the 
immaturity of the blood brain barrier which is yet to fully develop.  Children exhibit 
increased brain lead absorption and decreased lead excretion.  This is of particular 
concern based on recent findings from Canfield et al. (2003) confirming that even 
exposure below current allowable safety limits (10µg/dl) produce intellectual 
impairments in children.     
Lead Neurotoxicity 
Lead exposure in the living organism has various debilitating effects on the central 
nervous system.  When introduced into an organism, lead ions are primarily drawn to 
proteins that normally bind to either calcium or to zinc.  Sometimes these lead bound 
proteins become excessively active but in general lead tends to inhibit activity.  Known 
lead/zinc interactions are the inhibition of the zinc enzyme δ-amenolevulinic acid 
dehydratase [resulting in inhibition of the heme-biosynthetic pathway] (Warren et al., 
1998), transcription factor sites on several proteins, the human protamine 2 site affecting 
spermatogenesis (Quintanilla-Vega et al., 2000), and sites that affect DNA binding 
activity. Lead interactions with calcium suggest that it targets cells using calcium-
mediated signal transduction by competitive interference of depolarization-induced 
exocytosis of neurotransmitter (Manalis and Cooper, 1973).  Lead appears to promote 
phospholipid binding at lower concentrations than does calcium, particularly at the C2 
binding site located on calcium mediated proteins (Markovac and Goldstein, 1988). Lead 
is believed to affect calcium-dependent activation of protein kinase C (PKC). This could 
potentially impact numerous endpoints from cell growth to memory (Newton, 1995).   
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Glutamatergic Systems   
Glutamate is the primary excitatory neurotransmitter in the central nervous system.  Four 
types of glutamate receptors are presently thought to exist, the n-methyl-d-aspartate 
(NMDA), AMPA, and kainate receptor (all of which are ionotropic), and the 
Metabotropic Glutamate Receptor.  Lead toxicity appears to alter the NMDA receptor 
complex via noncompetitive blockade of calcium-mediated ion channels (Ujihara and 
Albuquerque, 1993).  This results in lower levels of stimulated glutamate release in 
animals chronically exposed to inorganic lead (Lasley et al., 1999; Lasley and Gilbert, 
2002).  Further, statistically significant decreased glutamate levels have been noted in the 
rat dorsal hippocampus, medial-basal hypothalamus, rostral neostriatum and brain cortex 
of maternally lead-exposed animals (Leret et al., 2002).  Interference with the NMDA 
receptor complex is also thought to affect thresholds for long-term potentiation (LTP), a 
cellular substrate of learning and memory (Gilbert et al., 1998). In addition, acute lead-
exposure may cause cellular apoptosis in the developing brain by means of NMDA 
blockade (Dribben et al., 2002). 
GABAergic Systems 
Gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the 
central nervous system. The system includes two primary types of receptors, GABAA 
(which acts on ionotropic chloride channels) and GABAB (which acts on metabotropic 
potassium channels).  Lead effects on the GABAergic system are similar to those of the 
glutamatergic system, acting primarily on voltage-dependent calcium channels.  
Decreases in the amounts of evoked GABA release seem to occur in the brains of animals 
exposed to chronic lead in areas such as the dorsal hippocampus (Lasley et al., 1999; 
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Lasley and Gilbert, 2002) and brain cortex (Leret et al. 2002).  Decreases in the pre-
synaptic uptake of GABA have also been noted, possibly due to a decreased number of 
synaptic vesicles or an altered mitochondrial structure (Jablonska et al. 1994).   
Dopaminergic Systems 
 Dopamine stimulates both inhibitory and excitatory postsynaptic potentials depending on 
the postsynaptic receptor.  Two types of dopamine receptors have been documented, D1-
like (includes D5) and D2-like (includes D3 and D4).  D1 receptors may be exclusively 
postsynaptic and D2 are found both post and presynaptically.  D1 stimulation increases 
second messenger cyclic-AMP whereas D2 stimulation decreases it.  Insults caused to the 
dopaminergic system by lead-exposure affect all aspects of neurotransmitter function.  
Changes are observed in dopamine synthesis (Jadhav and Ramesh, 1997), release (Zuch 
et al., 1998; Kala and Jadhav, 1995a) and binding (Pokora et al., 1996).  However these 
changes occur differently contingent on the lead-exposure period. Specifically, prenatal 
exposure results in increased dopamine and dopamine metabolite levels in discrete areas 
of the brain (Leret et al., 2002).  Adult exposure results in directionally opposite effects 
(Tavakoli-Nehzad et al., 2000) which result in D1 and D2 supersensitivity due to 
upregulation stemming from decreased synaptic dopamine levels (Cory-Slechta and 
Widzowski, 1991).  Several reports indicate that lead accumulation occurs in higher 
levels in the nucleus accumbens [NACC] (Kala and Jadhav, 1995b) and hippocampus 
(Gutowski et al., 1997; Leret et al. 2002; Stoltenburg-Didinger, 1994).  This is of 
particular importance in that the NACC is a known mediator of drug rewarding effects 
(Roberts and Koob, 1982).  Possible determinants include modulation of the calcium 
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dependent PKC 2 system (Ramin et al., 1993) or synaptic terminal auto-receptors 
(Lasley, 1992). 
Lead and Behavior  
Lead effects on central nervous system activity are, predictably, not without behavioral 
consequences.  As previously mentioned, lead toxicity is thought to affect LTP, which is 
model of learning and memory systems.  Disruptions from lead-exposure can lead to 
altered performance in tests that measure learning and memory (Salinas and Huff 2002a; 
Salinas and Huff 2002b). While there does not exist a sizable literature regarding lead 
and anxiety, known components of stress mechanisms are affected by lead toxicity.  
Specifically, lead effects on neurotransmitter mechanisms are thought to possibly affect 
stress reactivity or baseline anxiety levels in chronically exposed animals, in addition to 
locomotor activity and exploratory behavior (Moreira et al., 2001).  Lead treated animals 
also have exhibited impulsive behaviors or an inability to suppress incorrect responding 
(Brockel and Cory-Slechta 1997).  Pertinent to the present study, various alterations in 
schedule-controlled performance measures have been documented (Cory-Slechta, 1997).   
This pattern of behaviors prompted the examination of possible anxiety increasing 
properties of lead-exposure and the interaction with drug self-administration.   
Lead/Drug Interactions 
The widespread distribution of lead in urban areas coincides with a prevalence of drug 
use in these same areas and therefore merits closer examination (Ensminger et al., 1997).  
Animal studies have demonstrated numerous behavioral changes as a result of 
developmental exposure to lead at levels comparable to that of children who have been 
chronically exposed to the metal.  Mesocorticolimbic (neurons originating in the ventral 
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tegmental area [VTA] and terminating in the NACC and frontal cortex) systems are 
known to be integral in modulating the rewarding effects of drugs with abuse liability and 
also are known, as mentioned above, to be affected by lead toxicity.  Therefore it is 
hypothesized that lead burdens in the organism could possibly be affecting drug 
sensitivity or intake via altered molecular mechanisms.  In regards to this issue, lead 
aberrations have been determined to have interaction effects with psychomotor stimulants 
and opiates in various behavioral measures, however the period of exposure is crucial in 
mediating the resulting behaviors (Miller et al., 2000a; Miller et al., 2000b; Nation et al., 
2003a; Nation et al., 2003b; Rocha et al., 2003; Valles et al., 2003).  Developmental 
exposure to lead results in a more dynamic and sometimes directionally opposite pattern 
of effects when compared to post-weaning lead-exposure.   
Opiates 
Disruption of opioid ligand and receptor development and function occurs due to 
developmental and adult lead toxicity (Kitchen, 1993).  Adult animals exposed to 16 mg 
of lead acetate for 30 days resulted in a decreased magnitude of sensitization to the 
locomotor stimulating properties of repeated morphine administrations, even after blood 
lead had returned to control levels [<1µg/dl] (Miller et al., 2000b).  Examination of the 
conditioned reinforcing properties of morphine has revealed attenuation at doses of 1.25 
and 2.50 mg/kg by perinatal lead exposure to 16 mg lead acetate (Valles et al., 2003).  
These effects are further seen in a self-administration investigation using heroin, where a 
general suppression of responding was observed at intermediate intravenous [IV] doses 
(0.0023, 0.0045, 0.009, and 0.018 mg/kg/infusion) and in a progressive ratio preparation 
where attenuation was seen at all heroin doses [0.0023, 0.0045, 0.009, and 0.018 
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mg/kg/infusion] (Rocha et al., 2003). Since glutamate and dopamine are thought to aid in 
behavioral sensitization (Vanderschuren and Kalivas, 2000) and reinforcement (Bardo, 
1998) of opiates, lead insults to these systems are likely resulting in changes to 
neurotransmitter concentrations and efficiency.    
Neural Mechanisms of Cocaine 
The behavioral effects of cocaine appear to be mediated by blockade of the reuptake 
transporter in pre-synaptic dopaminergic neurons resulting in an accumulation of 
dopamine in the synaptic cleft.  Mesocorticolimbic neurons originating in the ventral 
tegmental area and terminating in forebrain areas are implicated in the rewarding effects 
of cocaine and other drugs of abuse (Bardo, 1998). Particular attention has been given to 
the NACC dopamine innervations (Roberts and Koob, 1982).  Both D1 (Koob et al., 
1987) and D2 (Bergman et al., 1990) receptor antagonism has resulted in an attenuation 
of the reinforcing properties of cocaine in self-administration preparations.  Recent 
investigations have also suggested that D1 and D2 receptors differentially mediate 
cocaine reinforcement.  Selective agonism of each receptor subtype produced downward 
(D1 agonist SKF 82958) and leftward (D2 agonist quinelorane) shifts in the cocaine 
dose-response curve (Caine et al., 2000).   
In addition to dopaminergic activity, an increasing body of literature exists 
detailing the modulation of dopamine levels via other neurotransmitter systems, including 
the GABAergic system (Rahman and McBride, 2002).  VTA GABAergic and 
gluatamatergic inputs originating in forebrain regions respond to D1 dopamine receptor 
blockade by decreasing cocaine reward, lending to the possibility of dendritically 
modulated dopamine cell activity by indirect stimulation (Ranaldi and Wise, 2001).  
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Glutamate stimulation in NACC is also thought to augment the hedonic value of cocaine 
but not be necessary for maintaining self-administration (Cornish et al., 1999; Pulvirenti 
et al., 1992).  Sensitization is known to occur via chronic administration of cocaine into 
NACC.  This is prevented using MK-801 (an NMDA antagonist) in VTA but not induced 
by NMDA agonism suggesting a vital, but not sole, role for VTA projections modulating 
dopaminergic terminals in NACC (Vanderschuren and Kalivas, 2000).  Both GABA and 
dopamine also have been shown to modulate cocaine-induced reinstatement, possibly via 
a dorsal prefrontal cortex-NACC core-ventral pallidum circuit (McFarland and Kalivas, 
2001).   
Cocaine  
Chronic administration of inorganic lead in the adult animal produces an attenuation of 
the locomotor stimulating effects of repeated administration of 10 mg/kg cocaine IP 
(Nation et al., 1996), and attenuation of schedule-controlled operant responding at an 
intermediate dose of 20 mg/kg cocaine intraperitoneal [IP] (Burkey et al., 1997).  Direct 
brain self-stimulation into the medial forebrain bundle is also diminished in animals 
exposed to lead as adults (Burkey and Nation, 1994).  In addition, extracellular dopamine 
levels in the NACC are attenuated by chronic adult lead-exposure (Nation and Burkey, 
1994).  This dopamine depletion results is manifested in schedule-controlled drug self-
administration as an attenuation to the decrements in responding produced by dopamine 
agonists (Cory-Slechta et al., 1996).  These findings support the position that adult 
inorganic lead-exposure causes dopamine depletions in brain areas mediating drug 
reward.  
9 
Elsewhere, animals exposed to lead throughout gestation and lactation (perinatal 
exposure) using 16 mg lead show an attenuation of the reinforcing properties of 1.25 and 
2.5 mg/kg cocaine [IP] in a conditioned place preference paradigm [CPP] (Miller et al., 
2000a).  Similar antagonism has been found in drug discrimination studies where 
perinatal lead-exposure has resulted in a subsensitivity to SKF-82958 (D1-like dopamine 
agonist), quinpirole (D2-like dopamine agonist) and apomorhine [D1/D2-like dopamine 
agonist] (Miller et al., 2001).  However, directionally opposite effects are seen in acute 
versus chronic cocaine exposure in developmentally lead-exposed animals.  Animals 
exposed to an identical lead-exposure protocol showed less responsiveness to the initial 
administration of cocaine but an augmentation of the stimulatory (locomotor 
sensitization) effects of repeated administration of 10.00, 20.00, and 40.00 mg/kg cocaine 
[IP] (Nation et al., 2000).  Increased sensitivity has also been shown in a cocaine 
reinstatement preparation.  Animals trained to self-administer 0.50 mg/kg cocaine [IV] 
were extinguished for 3 hours and then primed before the final test hour using either 0.00, 
5.00, 10.00, 20.00 mg/kg cocaine [IP].   Developmentally lead-exposed animals infused 
greater amounts of saline after receiving 5.00 and 10.00 mg/kg cocaine (Nation et al., 
2003b).  Most pertinent to the proposed study, animals exposed to 16 mg lead throughout 
gestation and lactation, demonstrated an elevated sensitivity to repeated cocaine self-
administration, manifested as a functional shift left from that of control animals in the 
dose-effect curve.  Lead-exposed animals responded at significantly greater rates for 0.06 
mg/kg cocaine, and at significantly lower rates for 1.25 and 2.5 mg/kg cocaine [IV] 
providing further supporting evidence that reinforcement mechanisms are altered so as to  
produce increased sensitivity in lead-treated animals (Nation et al., 2003a).  Data from 
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Lynch and Carroll (2001) have sited station factors as possible determinants for 
decreased responding to increased or functionally higher doses of drug.  It is important to 
note that in the Nation et al. (2003a) study, lead had gained clearance from tissues, yet 
the altered behavioral effect persisted.  These data point to relatively permanent neuronal 
alterations in cocaine/dopamine related circuitries occurring during a critical period of 
developmental lead-exposure. 
Anxiety 
Neurochemistry 
Stress can be defined as a physiological response to an aversive stimuli presented to an 
animal.  This response prepares the organism for a possibly dangerous situation by 
placing the body in a catabolic state.  While cardiovascular, immune, gastrointestinal and 
neuroendocrine systems are all affected in the presence of a stressor, for the purposes of 
this study the focus will be on neurotransmitters that modulate the hypothalamic-
pituitary-adrenal (HPA) axis.  The neuroendocrine response to stress begins with an 
increased secretion of epinephrine and norepinepherine from the sympathetic nervous 
system and adrenal medulla, followed by the release of corticotropin-releasing factors 
(CRF), vasopressin from parvicellular neurons into portal circulation, increased secretion 
of oxytocin from the pituitary and finally, 5-10 seconds later, adrenocorticotropin 
hormone (ACTH) is secreted by the pituitary which then enters general circulation and 
stimulates the adrenal gland to release adrenocorticosteroids (Sapolsky et al., 2000; Van 
de Kar and Blair, 1999). Among these are cortisol (in humans) and corticosterone (in 
rats).  CRF mRNA is expressed in various brain regions including cerebral cortex, 
paraventricullar nucleus of the hypothalamus, amygdala and hippocampus (Bittencourt 
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and Sawchenko, 2000).  Receptors for CRF include two types (CRF1 and CRF2) and are 
widely located throughout the central nervous system. High concentrations of CRF1 
receptors are found in the pituitary, cerebellum, brain stem, amygdala and cortex whereas 
CRF2 receptors are found predominantly in the lateral septum, choroids plexus, olfactory 
bulb, amygdala and hypothalamus (Chalmers et al., 1995; Perrin et al., 1993; Primus et 
al., 1997) CRF actions are mediated through G-protein linked receptors and antagonism 
is known to cause a decrease in ACTH and corticosterone (Gully et al., 2002, Kim et al., 
1998).   
GABA  receptors are also known to be integrally involved in mediation of stress 
and anxiety (Nutt and Malizia, 2001), possibly due to forebrain pathways directly 
involved in stress-induced hormone secretion (Van der Kar and Blair, 1999).  Stimulation 
of the GABAA receptor complex results in inhibition of ACTH secretion to various 
stressors (Rhoher et al., 1994; Yagi and Onaka, 1996). Agonism of benzodiazepine 
receptors in the dorsal hippocampus and median raphe nucleus produce anxiolytic effects 
in social interaction tests (Gonzalez et al., 1998) and elevated plus-maze tests, perhaps 
due to autoreceptor blockade leading to endogenous GABA mediated stimulation of post-
synaptic GABAA receptors (Zarrindast et al., 2001).  Intracranial antagonism of 
basolateral amygdala GABAA receptors using bicuculline methiodide results in 
conditioned place avoidance (Thielen and Shekhar, 2002).  Withdrawal of the GABAA 
neuroactive steroid allopregnanone has also resulted in increases in anxiety in plus-maze 
tests in male and female rats alike (Gulinello et al., 2002; Smith, 2002).  These studies 
implicate the HPA axis and GABA receptor complex as critical mediators of anxiety-like 
behaviors/states.    
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Cocaine/GABA/Anxiety Interactions 
Since GABA is a known inhibitor of mesolimbic dopamine neurons and GABA is, as 
previously discussed, a modulator of anxiety related mechanisms; it has been proposed 
that GABA manipulations can alter cocaine reinforcement via changes in endogenous 
dopamine function.  GABAB receptor agonists have resulted in a decrease in infusions in 
self-administration protocols using cocaine (Brebner et al., 1999) and direct brain 
stimulation reward (Dobrovisky et al., 2002). Moreover, this effect is attenuated by the 
GABAB antagonist CGP56433A in similar cocaine self-administration studies (Brebner 
et al., 2001).  Inhibitors of GABA transaminase have shown attenuation to both cocaine 
sensitization (Gardner et al., 2002) and CPP (Ashby et al., 2002) tests respectively.   
The use of diazepam (a GABAA agonist) in BALB/cByJ knockout mice 
exhibiting high levels of trait anxiety possibly acts as an anxiolytic and thereby decreases 
the rewarding value of cocaine, which subsequently is manifest as an increase in cocaine 
self-administration (David et al., 2001).  These same animals have also experienced 
facilitation to cocaine acquisition.  Further evidence of GABAA involvement in 
anxiety/rewarding interactions are presented in studies where frontal cortex stimulation of 
GABAA neurons resulted in attenuation of locomotor stimulating effects of cocaine 
(Karler et al., 1998).  Furthermore, GABAA ά1 subunit knock-out mice show no 
hypolercomotor response to cocaine (Reynolds et al., 2003).    
Evaluations of neuroendocrine mechanisms and cocaine reward also have yielded 
evidence to support an interaction between cocaine/GABA/anxiety.  Reactivity to low 
doses of cocaine may be augmented by increasing circulating levels of plasma 
corticosterone, functionally altering the efficacy of the drug (Goeders, 2002). CRF 
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receptor subtype 1 antagonists have been proven to block both the induction (Lu et al., 
2003) and reactivation of CPP (Lu et al., 2001).  Findings from Lu et al. (2003) further 
indicate that CRF antagonism decreases the locomotor response, stereotype counts, and 
extracellular dopamine levels in NACC and VTA to cocaine.  The effects of 
adrenalectomies on cocaine related behaviors parallels CRF antagonism as well 
(Przegalinski et al., 2000).  Along these lines, exposure to repeated stressful episodes 
increased the locomotor effects of cocaine, facilitated acquisition, prolonged responding, 
and increased the breaking point in a progressive ratio test (Covington and Miczek, 
2001).  Since anxiogenic factors have been known to alter the rewarding properties of 
cocaine (Goeders, 2002), the existence of an interaction between developmental lead-
exposure, GABA manipulation and cocaine self-administration is plausible.  
Accordingly, increases in anxiety have been examined as a possible factor in elevating 
the reward potency of cocaine.   
Self-Administration Procedure 
The intravenous self-administration procedure is generally accepted as a gauge of the 
reinforcing value of drugs with abuse liability.  The IV self-administration procedure 
allows the animal to maintain an optimal level of drug by regulating the amount of 
responding during a given session (Lynch and Carroll, 2001; Wise et al., 1995).  Free 
access to a drug produces an inverted U-shaped curve that visually represents averaged 
response rates to increasing concentrations of the drug.  Maximal levels of responding are 
present at optimal doses.  Further increases in drug concentration result in diminished 
responding (characterized as the descending limb of the dose-effect curve) perhaps due to 
a decreasing reinforcement value of the drug. Manipulations to the procedure that change 
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the reinforcing value of the drug are characterized as changes in the dose-effect curve.  
Typically, a shift left would indicate an increased potency whereas a shift right would 
indicate a decreased potency of the drug being tested.   
Design and Hypothesis 
In order to examine the underlying mechanisms that might be affected by perinatal lead-
exposure, this study employed a standard cocaine self-administration preparation in 
conjunction with a GABA receptor manipulation.  This procedure was aimed at 
expanding the understanding of the possible interactions between cocaine self-
administration and lead-induced shifts in anxiety related endocrine factors stemming 
from GABA modulation.    
Dams were developmentally (both during gestation and lactation) exposed to 
either 0 or 16 mg lead.  Offspring behavioral testing commenced testing at about 
postnatal day 70.  Each animal was trained on a baseline dose of cocaine [IV] and tested 
on alternating sets of two-day intervals using combinations of cocaine [IV] and 
bicuculline methobromide (a GABAA antagonist) [IP] until all combinations were tested.  
The antagonist bicuculline methobromide was administered to control and lead-exposed 
(Group 0-Lead and Group 16-Lead respectively) animals approximately 10 minutes prior 
to introduction into an operant conditioning chamber with a predetermined fixed-ratio 
(FR) schedule for cocaine infusions.  
Predictions 
The hypothesis of this study was that bicuculline (a selective GABAA antagonist) would 
augment the reward value of cocaine for both Group 0-Lead and Group 16-Lead. Because 
lead-exposed animals are known to respond differentially to low doses of cocaine in 
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contrast to non-exposed animals (Nation et al., 2003a), two doses (0.03 and 0.06 mg/kg) 
on the ascending limb of the dose-effect curve where chosen for testing (See Fig. 1). 
Depending on their functional position on the dose-effect curve at either cocaine dose, 
bicuculline pre-treatment would act as an anxiogenic and shift active lever response rates 
further to the left; i.e., increased reward potency.     
It was predicted that GABA antagonism would result in increased cocaine 
reinforcement efficacy via one/both of two possible mechanisms: dopaminergic 
disinhibition and activation of the HPA axis.  GABA antagonism in the brain, primarily 
in the VTA, would result in disinhibition of dopaminergic projections to the NACC (a 
vital location in mediating drug reward [Roberts and Koob, 1982]) resulting in increased 
dopaminergic activation.  Subsequently, increased reward potency would be experienced 
when cocaine (a dopamine reuptake inhibitor) was presented.  Also, GABA antagonism 
may possibly affect stress via forebrain pathways involved in hormone secretion (Van der 
Kar and Blair, 1999).  CRF circulation is critical in the stimulated release of ACTH 
which results in stimulation of andrenocorticosteroid release (Sapolsky et al., 2000; Van 
der Kar and Blair, 1999).  Increased CRF is known to increase cocaine reward potency 
(Goeders, 2002).  GABAA agonism results in inhibition of ACTH secretion (Rhoher et 
al., 1994; Yagi and Onaka, 1996); therefore GABAA antagonism by bicuculline would 
result in increased ACTH secretion and lead to increased reward potency.   
This increase in the hedonic value of cocaine would manifest itself differently in 
Group 0-Lead vs. Group 16-Lead animals.  As previously mentioned, differential 
responding (specifically an enhanced sensitivity) at low doses of cocaine is evident in 
lead-exposed animals.  At the 0.03 mg/kg cocaine dose, ascending concentrations of 
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pretreatment with bicuculline would result in increases in responding by both groups.  
However, Group 16-Lead was expected to reach optimal levels at a lower concentration 
of the antagonist.  At the 0.06 mg/kg cocaine dose, as concentrations of bicuculline 
ascended, responding in Group 0-Lead would increase while Group 16-Lead would 
decrease.   Possible simultaneous decreases at the highest dose of bicuculline (2.0 mg/kg) 
in combination with 0.06 mg/kg cocaine might result in responding that was not 
statistically different between groups.  This would be due to reward potency that had 
functionally approached or surpassed the 0.50 mg/kg dose of cocaine which is known to 
produce similar response rates in both non-exposed and lead-exposed rats (Nation et al., 
2003a). 
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Fig. 1  Perinatal exposure to lead alters self-administration responding to IV cocaine.  
Mean rates of responding for each group and standard error values.  The symbol * 
denotes statistical significance between groups at that dose (from Nation et al., 2003a). 
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MATERIALS AND METHODS 
Animals 
 
The research design and conduct of the experiment was approved by the Texas A&M 
University Laboratory Animal Care Committee, and all aspects of the research followed 
the guidelines outlined in Principles of Laboratory Animal Care (NIH publication No.85-
23). All animals were maintained on a 12 hour dark/light cycle consisting of lights on at 8 
am and lights off at 8 pm.  Adult female Sprague-Dawley (Harlan; Houston, TX) rats 
(dams) were exposed to 0 (sodium acetate) or 16 mg lead (as lead acetate) daily via 
gavage, disregarding animal body weight. This approach has been used in our laboratory 
successfully in order to approximate environmental exposure to humans, because human 
lead-exposure in the environment does not occur according to bodyweight.  A 16 ga 
gavage needle was used to administer the respective solutions in a volume of 1.0 ml 
deionized water at a pH of 5.5 for 30 days prior to breeding.  Upon completion of the 30-
day lead-exposure, non-exposed males were introduced into the home cage of the dam 
and lead-exposure of dams during breeding was continued as described.  Once dams 
tested positive for copulatory plugs, males were removed from the breeding cage. The 
lead exposure regimen for dams remained uninterrupted throughout breeding, gestation 
and lactation.  Pups were exposed to lead perinatally, having had transplacental exposure 
prenatally and no route of lead exposure other than the mother’s milk supply postnatally.  
Dams were maintained on standard rat chow and water ad libitum throughout experiment. 
Daily bodyweights and weekly food intake data were recorded and analyzed.   
On postnatal day (PND) 1, litters were culled to eight pups keeping the most 
males possible and using females if necessary to complete the litter.  Only one pup from 
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each dam was used in the study in order to avoid any litter confounds that could arise 
(Holson and Pearce, 1992).  Pups were weaned from the mother on PND 21 and housed 
two or three to a cage and placed on ad libitum food and water with no further exposure 
to lead.  On PND 50 pups were separated and individually housed for the remainder of 
the study.  Each animal had ad libitum access to food and water for the remainder of the 
study.  All animals were kept on a 12hr/12hr dark/light cycle for the entire investigation. 
Dams had tail-blood drawn in a volume of 100-150 µl at the onset of breeding, at 
10 days gestation and again at day one parturition (PND 1).  At weaning (PND 21), blood 
was collected via cardiac puncture and brain, liver, kidney, and tibia samples were 
harvested from dams.  Littermates were sacrificed at PND 1 and PND 21, and blood 
samples were used for later analyses.  On completion of the study, all test animals were 
sacrificed in order to obtain blood and tissue samples as described above. 
Surgery 
On PND 63, chronic indwelling jugular catheters were implanted in 12 control and 12 
lead-exposed male offspring. Rats were anesthetized with separate injections of 50 mg/kg 
ketamine and 50 mg/kg sodium pentobarbital administered intraperitoneally [IP]. A .01 
interior diameter [ID] Silastic tubing (Dow Corning, Midland, MI) catheter was inserted 
into the right jugular vein and sutured to muscle tissue in the area of the vein. Using an 
11 ga stainless steel tube as a guide, the catheter was passed subcutaneously through the 
body of the animal exiting the back between the scapulae.  A backplate consisting of two 
stainless steel ovals separated by polypropylene mesh (Ethicon, Inc.; Somereville, NJ) 
provided an anchor for a spring leash, through which the catheter was threaded. 
Connecting to the backplate at one end, the other end of the leash was connected to a 
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single channel fluid swivel [22 ga] (Instech Labs, Plymouth Meeting, PA). The swivel 
design permitted an interlock with separate connecting arms located in the home cage and 
operant test chambers. The hinged arm allowed for a range of movement in either the 
home cage or test chamber. A .02 ID catheter continued from the top of the swivel to an 
infusion pump (Razel Scientific Instruments; Stamford, CT) that controlled the solution 
delivery. Animals were allowed 7 days to recover from surgery before commencing 
cocaine self-administration testing on about PND 70. During this recovery period, each 
animal received automated hourly intravenous [IV] infusions (200 µl) of a sterile saline 
solution containing heparin (1.25 U/ml), penicillin g potassium (250,000 U/ml), and 
streptokinase (8,000 U/ml) in the home cage. After self-administration sessions, each 
cannulae were flushed with this solution, and then cleared with a subsequent infusion of 
500 µl heparinized saline. Catheter patency was checked throughout the experiment by 
administering an IV infusion of 7.50 mg/kg sodium pentobarbital.  Loss of consciousness 
confirmed patency of the catheter in the vein.   
Apparatus 
 
Twelve operant conditioning chambers (Model E10-10, Coulbourn, Allentown, PA) in 
sound attenuating cubicles served as the test apparatus. Each chamber contained two 
levers with a stimulus light above each on one side of the enclosure.  Drug delivery into 
the animal was controlled by an infusion pump (Razel Scientific Instruments; Stamford, 
CT) in each chamber.  A 20-ml syringe delivered IV infusions of 160 ul over a 6.00 sec 
time frame.  Two IBM computers monitored and recorded drug deliveries from the 
chambers.  Animals were run in two squads of 12 each, counterbalanced by group in 
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terms of squad assignment and chamber.  All behavioral testing occurred during the light 
phase of the dark/light cycle. 
Behavioral Testing 
 
Baseline training commenced with infusions of a 0.50 mg/kg concentration of cocaine 
HCL (administered as the salt).  Cocaine was suspended in a heparinized 0.9% saline 
solution.  The schedule began as a fixed ratio (FR)-1 lever press (equaling one infusion) 
and continued as such until daily responding was steady-state (< 20% fluctuation over 
7days) and then was switched to an FR-2 until steady-state responding again (< 20% 
fluctuation over 7days) was evident.  The dose of 0.50 mg/kg/infusion cocaine allowed 
for a rapid acquisition of the drug-response contingency.  Animals were given an initial 
manual infusion by the experimenter at the onset of the session and were administered 
another manual infusion if no response was scored for a period of time longer than 15 
min thereafter.   
 All sessions in the operant chambers were 2 hours in duration.  Responding at the 
appropriate FR on the active (right) lever resulted in a cocaine infusion and a 
simultaneous illumination of the stimulus light positioned directly above the lever.  
During training and testing, the houselights otherwise remained off.  Lever responding at 
any time on the inactive (left) lever had no consequences but were monitored and 
recorded.  A time out period (6.00 sec), in which further responding had no programmed 
consequences, was in effect during the duration of each infusion (160 ul over 6.00 sec) 
and responses during this period are not included in the analyses reported here.   
 Dose-effect testing commenced after stable baseline training was established 
(steady-state responding for FR-1 and FR-2). Cocaine test dose, GABA antagonist 
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(bicuculline) test dose, and squad assignment were counterbalanced across treatment 
conditions.  Squads continued to run in two squads of 12 each.  The schedule consisted of 
two days of testing with a combination of cocaine (0.03 or 0.06 mg/kg) [as indicated 
these doses were selected based on the previous data of Nation et al., 2003a) and the 
GABAA receptor antagonist bicuculline methobromide (0.00, 0.50, 1.00 and 2.00 mg/kg) 
followed by two days of baseline sessions in order to reestablish stable responding. 
Bicuculline methobromide was suspended in a 0.9 % saline solution.  Sessions continued 
until all combinations of 0.03 and 0.06 mg/kg cocaine and bicuculline had been 
completed.  Bicuculline injections were administered IP, 10 minutes prior to the onset of 
testing.    Animals were then placed into the operant conditioning chambers. The 
computers were then programmed to begin monitoring and subjects were given an initial 
manual lever prime.  All doors were then closed and the testing session officially began.  
 Prior to the self-administration session, the catheter connecting the infusion pump 
and the swivel was flushed with a 1 ml solution of 95% ethanol and a subsequent 1 ml 
solution of heparinized saline to clear the line.  The catheter was then reconnected to the 
syringe pump containing a freshly mixed dosing solution and filled completely with the 
new drug solution.  After the jugular catheter was connected to the swivel, it formed a 
closed drug delivery system.  The pump was then manually activated until the new 
solution was available to the animal for the initial infusion of cocaine by infusing the 
saline in the line into the animal.   
 Following the conclusion of the study, all animals were sacrificed using 50.0 
mg/kg pentobarbital [IP].  Blood samples were taken via cardiac puncture.  Brain, liver, 
kidney, and tibia were harvested and frozen at a temperature of -90º C.  Blood and tissue 
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were later acid digested and analyzed for lead residues using mass atomic absorption 
spectrophotometry (Dearth et al., 2002).  
Statistical Analyses 
Food intake and body weight data were analyzed using separate analysis of variance 
(ANOVA) tests. Weekly food consumption served as the dependent measures in a 2 
Groups (Group 0-Lead, Group 16-Lead) X (10 and 5) Weeks analyses.  Average weekly 
body weight served as the dependent measures in a 2 Groups (Group 0-Lead, Group 16-
Lead) X (11, 7 and 5) Weeks analyses 
Performance during testing sessions was analyzed using ANOVA repeated 
measures on 2 Groups (Group 0-Lead, Group 16-Lead) X 2 Cocaine Doses (0.03 and 
0.06 mg/kg) X 4 Bicuculline Dose (0.00, 0.50, 1.00, and 2.00 mg/kg) X 2 Levers (Active, 
Inactive) to determine if any main effects or interaction effects were present.  Within 
subject factors were Cocaine Doses (0.03 and 0.06n mg/kg), Bicuculline Doses (0.00, 
0.50, 1.00 and 2.00 mg/kg), and Levers (Active and Inactive).  Baseline responding was 
measured using a 2 Groups (Group 0-Lead, Group 16-Lead) X 8 Scores X 2 Levers 
(Active, Inactive) ANOVA to determine if any main effects or interaction effects were 
present.  Within subject factors were Scores and Levers (Active and Inactive).  Neuman-
Keuls post-hoc test procedures were performed when appropriate. Number of total lever 
responses was used as the dependent measure.  The statistical significance level was set 
at P<0.05 for all cases.  Only animals completing all test dose combinations were 
included in these analyses.  Due to animal deaths prior to finishing the entire study, 
Group 0-Lead retained N=10 and Group 16-Lead retained N=8 subjects.   
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Drugs 
 
Cocaine HCL was provided gratis by NIDA (Research Triangle Park, N.C., USA).  
Bicuculline methobromide was purchased from Sigma-Aldrich Co. (St. Louis, MO, 
USA).  Streptokinase and ampicillan sodium were purchased through the Texas A&M 
University Large Animal Veterinary Pharmacy.   
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RESULTS 
Body Weights  
Dam bodyweights were analyzed using a 2 Groups X 11 Weeks repeated measures 
analysis of variance (ANOVA).  No significant interaction effects were present [F(10, 
230)=0.58, P>0.05].  A significant main effect for Week was found [F(10, 230)=184.33, 
P<0.001].  Post-hoc analyses revealed that bodyweights increased significantly from 
Weeks 1 through 7 for both control and lead (Group 0-Lead and Group 16-Lead 
respectively) animals.  This was likely due to weight gains from maturation and later 
pregnancy.  In addition, significant effects were also present by Groups [F(1, 23)=14.98, 
P<0.01].  One-way ANOVAs indicated statistically significant differences from Week 1 
through 7.  By way of contrast, Weeks 8 through 11 showed no differences.  Together 
these data suggest different rates of body mass increases between groups until the 
animals reached stable bodyweights.  
 Pup bodyweights prior to onset of testing were analyzed with a 2 Groups X 7 
Week ANOVA.  No significant interaction effects [F(6, 96)=1.24, P>0.05]or Groups 
effects [F(1, 16)=0.96, P>0.05] were present. Main effects were observed for Week [F(6, 
96)=278.25, P<0.001].  Post-hoc tests indicated that pup bodyweights steadily increased 
from, Weeks 2 -6 for Group 0-Lead and Week 4-7 for Group 16-Lead, as they matured.  
Group 0-Lead and Group 16-Lead animals had mean bodyweights of 378.0 ± 45.8 and 
349.3± 48.0 g, respectively at onset of testing.   
Pup bodyweights throughout testing were analyzed using a 2 Groups X 5 Weeks 
ANOVA.  No significant interaction effects [F(4, 96)=0.54, P>0.05]or Group effects 
[F(1, 14)=0.13, P>0.05] were present. Main effects were observed for Week [F(4, 
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96)=75.94, P<0.001].  Post-hoc tests revealed that bodyweights increased during Weeks 
3-5 for Group 0-Lead and from Week 1 to Week 2 for Group 16-Lead. Group 0-Lead and 
Group 16-Lead animals had mean bodyweights of 448.6 ± 33.8 and 442.3 ± 24.1 g, 
respectively, at termination of testing and showed no significant differences. 
Food Intake  
Dam food intake was analyzed using a 2 Groups X 10 Weeks ANOVA.  No significant 
interaction effects [F(9, 207)=0.62, P>0.05]or Group effects [F(1, 23)=3.18, P>0.05] 
were present. Main effects were observed for Week [F(9, 207)=75.13, P<0.001].  Post-
hoc tests revealed that food intake increased from Week 5 through 7 and from Week 9 to 
10 for Group 0-Lead animals. This occurred during breeding weeks when males were 
also present in the homecage.  Increases during Week 9 through 10 were likely due to the 
ability of the developing pups to reach and eat from the food bins.  Group 16-Lead 
animals displayed the same pattern of increases in food consumption again indicating the 
presence of breeders and pups. 
Pup food intake was analyzed using a 2 Groups X 5 Weeks ANOVA.  No 
significant interaction effects [F(4, 64)=0.61, P>0.05]or Group effects [F(1, 16)=0.842, 
P>0.05] were present. Main effects were observed for Week [F(4, 64)=25.49, P<0.001].  
Post-hoc tests revealed that animals steadily increased in food consumption from Week 1 
through 5.  All animals were kept on a diet of 20 g of rat chow per day throughout testing 
therefore food intake was not monitored. 
Behavioral Data  
A preliminary four-way 2 Groups (Group 0-Lead and Group 16-Lead) X 2 Cocaine 
Doses (0.03 and 0.6 mg/kg) X 4 Bicuculline Doses (0.00, 0.50, 1.00 and 2.00 mg/kg) X 2 
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Levers (Active and Inactive) was used to analyze the behavioral data (not depicted).  
Main effects for Bicuculline Doses were not present [F(3, 48)=1.70, P>0.05].  Interaction 
effects were present for Bicuculline Doses X Groups [F(3, 48)=3.25, P<0.05].  This 
interaction is particularly significant in that it shows bicuculline differential rate-altering 
effects on active lever responding between Groups.   
 No interaction effects were observed for Cocaine Doses X Groups [F(1, 16)=1.34, 
P>0.05]. Cocaine Doses did show significant main effects [F(1, 16)=8.66, P<0.05].  
Overall, less responding occurred at the lower dose of 0.03 mg/kg cocaine.  This is 
congruent with previous studies in which 0.03 mg/kg cocaine maintained the lowest 
average rates of responding across all groups (Nation et al., 2003a).   
 Interaction effects for Levers X Groups were not evident [F(1, 16)=0.99, P>0.05].  
However, significant main effects did exist for Levers [F(1, 16)=127.73, P<0.001].  
These data illustrate that Inactive Lever was significantly less frequent than Active 
(cocaine) lever responding and in fact almost non-existent.  
 Effects for Bicuculline Doses Cocaine Doses approached but did not reach an 
acceptable level of significance [F(3, 48)=2.67, P>0.05].  Interaction for Bicuculline 
Doses Cocaine Doses X Groups were present [F(3, 48)=11.43, P<0.001] indicating 
alterations in response rates due to bicuculline, cocaine, and lead-exposure. Interaction 
effects were also present for Bicuculline Doses Cocaine Doses Levers X Groups [F(3, 
48)=9.76, P<0.05], further showing the that responding was maintained on the active 
lever.  These data prompted additional, more specific, analyses to be performed by 
Cocaine Doses (either 0.03 or 0.06 mg/kg) and without the inclusion of Inactive Lever 
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responses.  All other pertinent interactions did not reach acceptable levels of significance 
and are not reported here. 
0.03 mg/kg Cocaine     
Behavioral data for 0.03 mg/kg cocaine was analyzed using a 2 Groups (Group 0-Lead 
and Group 16-Lead) X 4 Bicuculline (0.00, 0.50, 1.00 and 2.00 mg/kg) Dose repeated 
measures ANOVA.  No significant effects were observed for Bicuculline Dose [F(3, 
48)=1.85, P>0.05]. Effects for Group did not reach statistical significance [F(1, 
16)=2.182, P>0.05].  Bicuculline Dose x Groups interaction effects were present [F(3, 
48)=4.36, P<0.05].  One-way ANOVAs revealed significant differences between Group 
0- and 16-Lead only at the 0.50 mg/kg dose of bicuculline [F(1,17)=5.74, P<0.05].  
Group 0-Lead animals showed statistically and systemically significant decreases in 
response rates from doses of 0.50 to 2.00 mg/kg bicuculline (16.22±2.54 and 10.50±1.73 
respectively). Group 16-Lead animals showed no changes in response rates for any dose 
of bicuculline when tested at a cocaine dose of 0.03 mg/kg. 
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Fig. 2  Mean response rates and standard error values for Group 0- and 16-Lead at 0.03 
mg/kg/infusion cocaine and bicuculline.  The symbol * denotes statistical difference 
between groups. The symbol # denotes difference within Group 0-Lead at bicuculline 
doses of 0.50 and 2.0 mg/kg IP. Group 16-Lead did not produce altered response rates at 
any dose of bicuculline. 
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0.06 mg/kg Cocaine 
Repeated measures ANOVAs were performed using 2 Groups (Group 0-Lead and Group 
16-Lead) X 4 Bicuculline (0.00, 0.50, 1.00 and 2.00 mg/kg) Dose.  Tests revealed no 
statistically significant main effects for Bicuculline Dose [F(3, 48)=1.92, P>0.05] or 
Group effects [F(1, 16)=0.00, P>0.05].  Interaction effects were apparent [F(3, 48)=6.92, 
P<0.05] however. 
 One-way ANOVAs indicated significant separation between Group 0- and 16-
Lead at the 0.0 mg/kg dose of bicuculline [F(1, 17)=10.42, P<0.01] and 1.00 mg/kg dose 
of bicuculline [F(1, 17)=4.66, P<0.05].  Group 0-Lead post-hoc analysis showed 
statistically relevant increases from Bicuculline Dose 0.00 to 1.00 mg/kg (10.84±1.77 and 
21.48±4.60 respectively).  Post-hoc tests performed on Group 16-Lead show significant 
decreases in active lever responding from Bicuculline Dose 0.00 (23.78±3.91) to both 
0.50 (10.11±1.31) and 1.00 mg/kg (9.41±2.35).   
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Fig. 3  Mean response rates and standard error values for Group 0- and 16-Lead at 0.06 
mg/kg/infusion cocaine and bicuculline.  The symbol * denotes statistical differences 
between groups.  The symbol # indicates statistical increases in response rates from 0.00 
mg/kg bicuculline IP in Group 0-Lead animals. The symbol + indicates statistical 
decreases in responding from 0.00 mg/kg bicuculline IP in Group 16-Lead. 
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0.50 mg/kg Cocaine 
Baseline (0.50 mg/kg cocaine) data collected between the respective tests were analyzed 
using a 2 Groups (Group 0-Lead and Group 16-Lead) X 8 Scores X 2 Levers (Active and 
Inactive) repeated measures ANOVA.  No effects for Scores [F(7, 112)=1.81, P>0.05] or 
Group effects [F(1, 16)=0.09, P>0.05] were evident.  Main effects were present for Lever 
[F(1, 16)=116.53, P<0.05] indicating that inactive lever responding was insignificant.  
Theses results parallel findings from Nation et al. (2003a), in which 0.50 mg/kg cocaine 
showed no differences in response rates between groups.  All other results were 
statistically insignificant and were not reported here.  
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Fig. 4  Mean baseline responding rates and standard error values for Groups 0- and 16-
Lead at 0.50 mg/kg/infusion cocaine.  Collapsed baseline responding between test 
sessions showed no statistical differences at any point. 
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Blood and Tissue 
It is apparent from Tables 1 and 2 that dams and pups showed greater concentrations of 
lead accumulation in blood in Group 16-Lead.  Due to a sampling error, termination 
blood and tissue in subjects is not presented.  However, numerous studies using this 
procedure have shown no difference in blood, brain and liver lead levels upon completion 
of test procedures (Nation et al., 2003a; Nation et al., 2003b, Rocha et al., 2003; Valles et 
al., 2003) even though behavioral effects persisted well into the adult life cycle (Nation et 
al., 2000). 
 
 
Table 1  Mean blood lead levels for Group 0- and 16-Lead dams at breeding, gestation 
10, PND 1 and PND 21.   
Dams Group 0-Lead Group 16-Lead 
Breeding 2.5±0.9 µg/dl 54.3±3.7 µg/dl * 
Gestation Day 10 2.0±0.3 µg/dl 44.6±3.0 µg/dl * 
PND 1 2.4±0.6 µg/dl 62.0±5.6 µg/dl * 
PND 21 3.0±1.3 µg/dl 23.6±1.4 µg/dl * 
*  Indicates statistical significance from Group 0-Lead at same sampling day. 
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Table 2  Blood lead levels for Group 0- and 16-Lead littermates at PND 1 and 21. 
Littermates                             Group 0-Lead                  Group 16-Lead 
 
PND 1                                     1.6±0.3 µg/dl                   46.3±8.4 µg/dl  
 
PND 21                                     1.2±0.2 µg/dl                   11.2±1.6 µg/dl   
*  Indicates statistical difference from Group 0-Lead on that sampling day. 
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DISCUSSION 
Intravenous [IV] cocaine deliveries at both the 0.03 and 0.06 mg/kg dose in combination 
with 0.00 mg/kg bicuculline intraperitoneal [IP] replicated findings from Nation et al. 
(2003a) inasmuch as lead-exposed (Group 16-Lead) animals maintained responding at 
higher rates at these low doses of cocaine.  A functional shift left of the dose-effect curve 
was evident in that Group 16-Lead animals lever pressed significantly more at 0.06 
mg/kg cocaine and 0.00 mg/kg bicuculline combination than control (Group 0-Lead) 
animals. Increasing concentrations of bicuculline in combination with 0.06 mg/kg 
cocaine produced directionally opposite effects for both groups as illustrated in Fig. 2 by 
the systemically increasing rates of responding by Group 0-Lead and decreasing rates of 
responding by Group 16-Lead animals.   
 Brain regions such as the nucleus accumbens (NACC) have long been implicated 
in cocaine reward (Wise and Bozarth, 1987), however increasing data point to other 
systems as modulators of cocaine neurochemical effects. Modulation of the GABA 
receptor complex is known to alter anxiety and stress related behaviors.  Stimulation of 
GABAA and GABAB receptors act as anxiolytics (Gonzalez et al., 1998) and are thought 
to decrease cocaine reward (Brebner et al., 1999; David et al., 2001; Zarrindast et al., 
2001).  Bicuculline anxiety promoting properties, via antagonism of GABAA receptors, 
have been documented (Thielen and Shekhar, 2001) and are the cornerstone of this study.  
GABA modulation of mesocorticolimbic dopaminergic pathways has been shown to alter 
cocaine reinforcement by stimulating dopamine neurons in areas known to be integral in 
drug efficacy (Ranaldi and Wise, 2001).  Mechanisms altering corticotropin-releasing 
factors (CRF) affect adrenocorticotropin hormone (ACTH) release, which result in 
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secretion of adrenocorticosteroids from the adrenal gland (Gully et al., 2002; Kim et al., 
1998).  Modulation of this system, the hypothalamic pituitary-adrenal-cortical (HPA) 
axis, is known to produce altered behaviors in cocaine testing preparations (Goeders, 
2002).  Since anxiety and stress behaviors are possibly influenced by GABA activity 
(Nutt and Malizia, 2001; Smith, 2002; Thielen and Shekhar, 2001), it is possible that the 
GABAergic system is involved in the neuroendocrine cascade resulting from a stress 
response.    
Differential sensitivity to cocaine at the 0.06 mg/kg dose was present prior to the 
administration of bicuculline due the developmental effects of lead on brain 
neurotransmitter systems.  Lead ions bind to calcium-mediated proteins including GABA 
receptors in the central nervous system (Godwin, 2001).  Lead toxicity causes deficits in 
GABA availability (Lasley et al., 1999; Lasley and Gilbert, 2002) and possibly increases 
the reward value for psychomotor stimulants by changing anxiogenic properties.  Lead 
increases dopamine binding in NACC (Pokora et al., 1996) and numbers of dopamine 
neurons in the ventral tegmental area [VTA] (Tavakoli-Nezhad et al., 2001) adding to the 
potential for increasing the reward value of drugs of abuse.  Behavioral manifestations, as 
they relate to cocaine self-administration, of such a pattern of neuronal alterations can be 
seen in Nation et al. (2003a).  Therefore, functionally, either treatment group was 
operating at different levels of the dose-effect curve, which can account for the pattern of 
responding that resulted from cocaine/bicuculline/lead interactions seen in this 
investigation.  Group 0-Lead animals at the 0.06 mg/kg cocaine dose were on the 
ascending limb of the curve, 1.25 mg/kg being their optimal dose (See Fig. 1).  Group 16-
Lead animals, due to the shift left, were experiencing 0.06 mg/kg cocaine as their peak 
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responding dose (see Fig. 1).  Peak responding and the descending portion of the dose-
effect are thought to represent satiation effects by the animal to increasing doses of drug 
(Lynch and Carroll, 2001).  This would further suggest that any increase in the rewarding 
properties of the drug would drive Group 0-Lead animals up and possibly over the 
ascending limb of the dose-effect curve.  Group 16-Lead animals would only show a 
decrease in responding as they are already responding at peak levels.  Therefore the 
resulting behavioral data for 0.06 mg/kg cocaine are in line with our predictions that 
Group 0-Lead animals would show increasing, while Group 16-Lead animals would 
show decreasing response rates due to functionally higher reward value of 0.06 mg/kg 
cocaine and increasing concentrations of bicuculline.  Since bicuculline is thought to 
cause a potentiation of cocaine reward value either directly via dopamine disinhibition or 
indirectly via neuroendocrine stimulation of the HPA axis, it is possible that GABA/lead 
interactions were synergistically increasing cocaine reward.  The data from this study 
parallel this explanation as shown in Fig. 2.   
 Findings from the 0.03 mg/kg cocaine and bicuculline combinations are less 
compelling.  While the combination with 0.00 mg/kg bicuculline showed no differences 
between groups as hypothesized, 0.50, 1.00, and 2.00 mg/kg combinations did not 
produce the predicted trends.  In other words, no apparent increases in responding were 
evident for Group 0-Lead animals.  Specifically, only a decrease was shown at the 
highest dose of bicuculline (See Fig 3.). On the whole, it did not appear that the 
rewarding properties of cocaine were increased for Group 16-Lead animals, since there 
were no changes in response rates at any bicuculline dose.  Perhaps the 0.03 mg/kg dose 
of cocaine is just too low to be affected by GABA antagonism. 
39 
 The results from this study lend to the burgeoning literature that implicates the 
interaction of various neurotransmitter and neuroendocrine systems in the mechanisms 
underlying the reward value of drugs of abuse.  Increases in GABA availability 
(Gerasimov et al., 2000) and GABAB receptor agonism (Brebner et al., 2000) have been 
known to diminish the reward value of cocaine by decreasing dopamine stimulation.   
As a result, GABA agonists have the potential for functioning as possible treatments for 
drug addictions (Brebner et al., 2002; Cousins et al, 2002).  The present behavioral data 
further explicate the anxiety altering properties of the GABA complex and its interaction 
with cocaine and developmental lead-exposure.  Specifically, antagonism may result in 
indirect increases in rewarding value of drugs with abuse liability.  Data from the 0.06 
mg/kg cocaine dose illustrate the response rate-altering effects of bicuculline in two 
groups of animals experiencing functionally different reward values for low doses of a 
psychomotor stimulant.   
  These data may be relevant to the human population.  Lead contamination 
continues to be a problem in industrialized nations and particularly in urban areas 
(Harwell et al., 1996; Pirkle et al., 1998).   The coincidence of drug abuse problems with 
elevated lead-exposure vectors in the inner city are cause for further investigation into 
possible interactions.  Children in particular are susceptible to the debilitating effects of 
lead-exposure and have been known to show cognitive deficits with blood lead levels 
below current allowable safety limits (Canfield et al., 2003).  Along these lines lead-
exposure both developmentally and in adulthood are showing increasing evidence of 
modulating brain areas associated with drug reward and anxiety mechanisms.   
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 In conclusion, further research is necessary in developing a complete 
understanding of cocaine/anxiety/lead interactions.  Tests measuring anxiety levels in 
perinatally lead-treated animals receiving GABA agonist or antagonist pretreatments are 
needed in order to determine anxiety/cocaine interactions in protocols similar to the one 
used here.  Additional measures of reward value using intra-cranial administration could 
implicate specific brain areas or systems in this complex set of interactions.    
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